In apparent efforts to expand the usefulness of polymers in medical applications during recent years, the term «controlled» drug release or drug delivery has been applied increasingly, both correctly and incorrectly. Correctly used, the term «controlled» refers specifically to the control of the rates whereby drugs are released from various mechanical, osmotic, biodegradable, or diffusional systems. Bagnall (1) in 1977 perceived the confusion and proposed a classification scheme of controlled drug release systems by specifically excluding sustained, delayed, or repeat-action preparations or delivery modalities, and restricting the term «controlled» to rates. Earlier, Baker and Lonsdale (2) drew a distinction between controlled release and sustained (or prolonged) release, the former being determined by the device itself, whereas the latter by various environmental conditions in the body by complexation, coatings, etc. In 1980 Rhine et al.
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(3) further restricted it by adding the caveat of zero-order (constant release) kinetics over specified periods of time. Heller and Baker (4) as well as others studied drug release from synthetic polymeric matrices by «bioerosion» (surface degradation), but it remains to be seen to what extent it can be «controlled» in vivo without formation of toxic metabolic products from the polymers and without other adverse effects. The significance of constant rate kinetics for specified time periods, even in modulated (variable rate) systems, was emphasized by Langer and Peppas (5) when discussing the classification and engineering aspects of various drug release systems, particulartv those that function by diffusional mechanism.
The pharmaceutical industry is, of course, interested in all kinds of drug release systems, ranging from tablets and capsules that release drugs into the gastrointestinal tract, to devices that can release drugs directly into the cirCUlatory system, or enter the circulation by the percutaneous route. Indeed, there are a few systems that are controlled release modalities, notably percutaneously administered prophylactic doses of nitroglycerin and scopolamine from polymeric diffusional release systems; implantable osmotic and mechanical pumps; and mechanically driven syringes, especially for insulin therapies. However, many others are nothing more than improved versions of sustained, prolonged, or repeat action formulations but without the pharmacokinetic profiles characteristic of controlled drug release systems. It would appear that the latter terminology has become a preferred catch phrase from a commercial viewpoint that tends to confuse clinicians as well as others who may be less acquainted with these differences. A recent paper by Lilienfield and Zapolski (6) is illustrative of the point in which an improved sustained-release oral formulation of the antitussive agent, dextromethorphan, under evaluation was referred to as «controlled» drug release. There are many other such misnomers in the literature, too numerous to mention here.
In my recent book (7), I as well as other contributing authors notably Yum and Wright (8) and Ueno and Refojo (9), carefully restricted the term «controlled» to ratecontrol, especially by constant-rate (zero-order) kinetics, for prescribed periods of time to maintain therapeutically effective dose levels, including so-called modulated systems that can release drugs at variable rates as well as constant rates at preselected time intervals (for example, insulin during preprandial and postprandial periods). Additionally, in my chapter (10) , I emphasized that just because a particular drug is released from a system by constant-rate or variable-rate (modulated) kinetics, this does not necessarily mean that the drug will be absorbed in the body in therapeutically optimal levels. Unfortunately, most papers in the literature dealing with controlled drug delivery place disproportionate emphasis on polymer chemistry and engineering aspects of the problem with often little or no regard to therapeutics. In fact, the body is often regarded as a hydrolytic machine that is capable of eliminating almost any synthetic polymer carriers that presumably can cleave or degrade in the physiological environment by simple hydrolysis, without any ill-effects on the metaboilc functions of organs. Such simplistic approaches tend to confuse the field and promise more than they can reasonably be expected to deliver. More often than not, such problems as bioavailability and toxic degradation products of polymeric carriers are either ignored or de-emphasized. These problems are, however, of primary importance especially in so-called targeted drug delivery systems aimed at functioning on the cellular level. These include liposomes, magnetic microencapsulated drugs, and others. In my view, time has arrived to separate out those systems that could realistically function in the living organism with therapeutic effectiveness from those that ignore the latter. As it now stands, despite many valuable possibilities, the literature is cluttered by descriptions of drug release systems, many of which may be of engineering interest 0391-3988/600173-02$00.50/0 but unrealistic from the standpoints of physiology, pharmacology and therapeutics. The readership of this Journal would benefit from contributions that do not ignore the latter areas with controlled or targeted drug release systems. 
